Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases

doi:10.19803/j.1672-8629.20240887

Abstract

Abstract: Objective To analyze the adverse drug reaction (ADR) signals of cefradine for injection so as to provide a clinical reference for safe medication. Methods The ROR and BCPNN Methods were employed to mine and analyze signals in cefradine-related ICSRs collected between 2017 and 2023 by safety databases based on real-world data from medical institutions. Results A total of 268 cases were included, and a total of 15 overlapping signals were detected by both ROR and BCPNN Methods. Among them, there were 7 safety signals identified as expected ADR that were specified in package inserts, namely haematuria, injection-site pain, hypersensitivity, vomiting, nausea, abdominal discomfort and abdominal pain. Meanwhile there were 8 unexpected safety signals identified, including temperature intolerance, tachypnoea, chills, pallor, hypoaesthesia, swelling, dizziness and flushing. Conclusion When cefradine for injection is clinically used, dosage regimens should be determined based on the patient’s conditions. Special care has to be given to those patients who are male, or under 18 or taking a combination of drugs. Changes in urinary routine indexes and renal function should be monitored to prevent such ADR as haematuria. In addition, clinicians should provide pharmaceutical care and remain alert to unexpected potential risks in order to ensure the safety of patients.

Key words: Cefradine for Injection, ROR, BCPNN, Signal Mining, Haematuria, Temperature Intolerance

CLC Number:

R951
R994.11

LI Qiurong, FU Miaoqing, ZHOU Baishui, LI Cui, XIAO Xiaotong, YU Yuping, DENG Lu. Mining of Real-World ADR Signals Related to Cefradine for Injection in 268 Cases[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 790-793.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240887

https://zgywjj.magtechjournal.com/EN/Y2025/V22/I7/790

References

[1] Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia Clinical Medication Guidelines: 2020 Edition. Volume of Chemical Drugs and Biological Products(中华人民共和国药典临床用药须知:2020年版.化学药和生物制品卷)[M]. Beijing: China Medical Science Press, 2022.
[2] QI XJ, ZHAO JL, FANG CS, et al.Meta-Analysis of Adverse Reactions Induced by Cefradine[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2019, 36(15): 1919-1926.
[3] XIA XD, LIU PC, ZHOU M, et al.Comparative Study on Signal Detection Methods Based on Real-World Date of Adverse Drug Reaction in H Province[J]. China Food and Drug Administration Magazine(中国食品药品监管), 2023(10): 42-55.
[4] XIA LF, LI Y, LI KL, et al.Fame Bias in Proportional Imbalance Analysis for Adverse Drug Reaction Signal Detection and Its Impact[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2022, 28(6): 730-735.
[5] YE XF.Progress and Considerations in Post-Marketing Adverse Drug Reaction Signal Detection Methods[J]. Academic Journal of Naval Medical University(海军军医大学学报), 2022, 43(2): 117-122.
[6] WANG DX, MA DD, QU H.Exploration of Adverse Drug Reaction Risk Signals Based on Reporting Odds Ratio Method in a City[J]. Journal of Pharmaceutical Research(药学研究), 2021, 40(8): 557-560.
[7] YANG HX, REN JX, HUANG XM, et al.Mining Adverse Reaction Signals of Blood-Activating and Stasis-Removing Traditional Chinese Medicine Injections Based on Reporting Odds Ratio Method[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2024, 33(8): 583-587.
[8] ZHOU YJ, LIU L.Mining Pharmacovigilance Signals of Etanercept Based on BCPNN Method[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(18): 1923-1926.
[9] DAI R, ZHANG QX, HU Y, et al.Investigation and Analysis of Research Design Issues in Domestic Literature on Adverse Drug Reaction Signal Detection[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2023, 25(8): 475-481.
[10] YOU CK, ZHOU TH.Clinical Case Reports of Hematuria Induced by Cefradine for Injection[J]. Journal of North Pharmacy(北方药学), 2016, 13(4): 125-126.
[11] WANG QF.Pharmacological Mechanisms of Cefradine-Induced Hematuria: an Adverse Drug Reaction Analysis[J]. Chin Med Guide(中国医药指南), 2019, 17(23): 62-63.

[1]	SUN Yinghao, ZANG Shuangyao, YU Wenhui, GUO Shuai, LI Tingting, ZHANG Yi, ZHANG Tingjian, MENG Fanhao. Effects and Challenges of Pharmacology and Toxicology of Aconitum Diterpenoid Alkaloids [J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 601-607.
[2]	ZHONG Ling, ZENG Huiyan, YUAN Xin, WANG Yingyan. Adverse Event Signals of Liraglutide and Semaglutide Based on the FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 305-312.
[3]	SUN Ximu, ZHOU Han, LI Yanming, GUO Peng, NIE Xiaolu. Signal Mining and Analysis of ICIs-Associated Thrombocytopenia Adverse Events Based on FAERS Database [J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 23-28.
[4]	ZHONG Hong, CHEN Hong, ZHANG Xuanyi, DENG Huiyuan, LUO Xianglin, WAN Jie, KONG Wenqiang. Detection and analysis of signals of adverse events induced by deferasirox based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 931-935.
[5]	HUANG Wei, LUO Yaqin, YU Xinyang, DONG Hongjing, WANG Xiao. Mechanisms of extracts of Pith-nodecayed and Pith-decayed of Scutellariae Radix against Th17/Treg immune imbalance in damp-heat ulcerative colitis rats [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 535-539.
[6]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[7]	CHEN Chongze, ZHOU Tianyu, SUN Siman, GUO Shushu, JIN Hongtao. Risk Signal Mining of Adverse Events Related to Levothyroxine Sodium Tablets Based on FAERS [J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1425-1431.
[8]	GUO Yijun, CHEN Xia, MENG Ping. Adverse drug reaction reports in 141 cases of orally administered targeted anti-tumor drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1137-1142.
[9]	YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin. Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
[10]	PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia. Comparison of likelihood ratio tests in post-marketing safety surveillance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
[11]	ZHANG Qingxia, ZHOU Liujun, LI Xiaoling, WANG Yuqin. Cefoperazone/sulbactam-related medication errors in the elderly and countermeasures [J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 574-578.
[12]	YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing. Safety of sugammadex for reversal of neuromuscular block based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
[13]	DING Qian, LI Boyu, ZHANG Qingxia. Risks to storage of nitroglycerin after unsealing and ways of prevention [J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 326-330.
[14]	HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua. Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
[15]	ZHANG Xuanyi, KONG Wenqiang, ZHONG Hong, DENG Huiyuan, SHU Yunfeng. Signal mining of adverse drug events of abiraterone based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1148-1153.